Nevertheless, PC-ALCL must be distinguished from secondary skin lesions in systemic ALCL, which confer a poor prognosis, and other CD30+ PCLPDs, reactive conditions, or borderline cases. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.